William Blair analyst Y Katherine Xu came out with a favorable report on Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA), after the company announced updated clinical data on its investigational …
The American Association of Clinical Oncology conference is wrapping up in Chicago. The three day conference brings together thousands of oncology professionals and …
Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA) announced updated clinical data on its investigational tyrosine kinase inhibitor (TKI), brigatinib (AP26113), in patients with anaplastic lymphoma kinase …
Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA) reported a first-quarter 2015 loss of 28 cents per share, a penny wider than the Zacks Consensus Estimate and …
J.P.
ARIAD Pharmaceuticals, Inc. (NASDAQ:ARIA) reported financial results for the first quarter of 2015, including revenue from sales of Iclusig® (ponatinib).
ARIAD Pharmaceuticals, Inc. (NASDAQ:ARIA) announced that it has reached an agreement to settle its current proxy contest with Sarissa Capital Management.
ARIAD Pharmaceuticals, Inc. (NASDAQ:ARIA) announced that its founder, Harvey J.
ARIAD Pharmaceuticals, Inc. (NASDAQ:ARIA) announced the issuance of its first U.
ARIAD Pharmaceuticals, Inc. (NASDAQ:ARIA) announced the results of a series of preclinical studies on its investigational tyrosine kinase inhibitor (TKI), brigatinib (AP26113) at …
